1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Danaher Corporation

Danaher Corporation

DHR
Danaher CorporationUS flagNew York Stock Exchange
203.41
USD
-0.49
- -
142.99BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
26.27
18.32
20.68
24.42
22.3
24.33
25.05
31.55
34.71
36.74
32.44
32.66
34.47
35.47
Basic EPS, GAAP
3.87
3.7
4.81
3.69
3.58
3.78
4.11
4.97
8.77
9.8
6.44
5.33
5.07
5.66
Free Cash Flow per Basic Share
4.38
4.69
4.71
4.24
4.18
4.91
4.64
7.67
9.96
10.21
7.85
7.24
7.38
7.72
Dividend per Share
0.07
0.32
0.51
1.28
0.54
0.62
1.05
0.87
1.04
1.13
1.69
1.05
1.23
1.36
Book Value per Share
32.07
33.19
34.49
33.23
37.84
40.22
41.22
51.33
58.6
66.48
72.36
68.9
74.32
74.81
Tangible Book Value per Share
0.14
0.92
-11.46
-18.26
-15
-6.63
-5.45
-28.42
-30.95
-11.92
-12
-13.24
-11.93
-23.03
Basic Weighted Avg Shares
696
702
698
691
696
701
715
706
715
725
736
731
713
708
Sales/Revenue/Turnover
18,283
12,867
14,434
16,882
15,519
17,049
17,911
22,284
24,802
26,643
23,890
23,875
24,568
25,107
Operating Margin (%)
17.07
15.89
14.98
16.2
16.58
17.92
18.25
18.99
25.75
28.29
21.77
20.37
19.09
20.42
Depreciation Expense
851
718
881
1,128
1,117
1,178
1,189
1,775
2,062
2,132
2,166
2,352
2,447
2,531
Net Income, GAAP
2,695
2,598
3,357
2,554
2,492
2,651
3,008
3,646
6,433
7,209
4,764
3,899
3,614
4,004
Effective Tax Rate (%)
24.17
21.45
14.35
17.54
14.59
18.77
26.41
18.89
16.34
11.45
16.32
16.08
14.95
16.21
Profit Margin (%)
14.74
20.19
23.26
15.13
16.06
15.55
16.79
16.36
25.94
27.06
19.94
16.33
14.71
15.95
Working Capital
4,586
4,035
1,666
-209
2,058
2,252
20,664
6,400
3,508
7,494
5,663
2,699
5,949
5,276
LT Debt
3,437
3,402
12,025
9,674
10,327
9,688
22,156
21,978
23,057
19,858
17,661
16,468
19,495
25,147
Total Equity
22,451
23,450
23,764
23,077
26,368
28,227
30,282
39,777
45,177
50,090
53,490
49,550
52,541
52,592
Return on Invested Capital (%)
9.36
6.01
5.76
6.23
6.04
6.59
5.27
5.95
8.13
9.52
6.02
5.8
5.71
5.78
Return on Capital (%)
11.12
10.11
10.94
7.52
7.23
7.38
6.8
6.74
10.16
10.62
6.96
5.92
5.53
5.71
Return on Common Equity (%)
13.02
11.36
14.27
10.94
10.1
9.72
10.34
10.77
15.99
15.73
9.31
7.57
7.08
7.63

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
201
923
1,411
LT Borrowings
18,416
17,561
25,147
LT Finance Leases
1,079
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
707
708
703
Market Capitalization
161,824
134,180
133,888

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
12,756
13,935
13,381
Cash, Cash Equivalents & STI
4,615
5,701
4,348
Accounts Receivable, Net
3,913
3,819
3,965
Inventories
2,489
2,608
3,260
Total Current Liabilities
6,807
7,460
8,105
Payables & Accruals
2,451
6,537
6,694
ST Debt
201
923
1,411
Deferred Revenue
1,353
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.7%
5.98%
6.04%
Free Cash Flow
7.08%
0.88%
-0.68%
Net Income, GAAP
4.38%
5.82%
-7.31%
Sales/Revenue/Turnover
5.95%
2.25%
2.9%
Total Cash Common Dividend
22.81%
18.62%
14.32%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,796
5,743
5,798
6,538
23,875
2025
5,741
5,936
6,053
6,838
24,568
2026
5,951
6,265
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.47
1.23
1.13
1.5
5.33
2025
1.33
0.77
1.28
1.69
5.07
2026
1.45
1.23
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.27
0.27
0.27
1.05
2025
0.27
0.32
0.32
0.32
1.23
2026
0.32
0.4
- -
- -
- -

Company Description

APIChatGPT
CEO
Rainer Blair
Full Time Employees
59,000
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
2200 Pennsylvania Avenue, NW Washington DC United States of America 20037-1701
IPO Date
Dec 29, 1978
CIK
0000313616
Website
danaher.com
Similar Companies
Chembio Diagnostics, Inc. (CEMI)
RushNet, Inc. (RSHN)
BioMark Diagnostics Inc. (BMKDF)
Biodesix, Inc. (BDSX)
Australian Clinical Labs Limited (ACL.AX)
Burning Rock Biotech Limited (BNR)
Business
Danaher Corporation (NYSE: DHR), founded in 1984 and headquartered in Washington, D.C., operates as a leading global science and technology innovator focused on life sciences and diagnostics. The company conducts business through three primary segments: biotechnology, which develops products and services for therapeutic development including bioprocessing solutions, plasmid DNA, mRNA, proteins, and genomic medicines via brands such as Cytiva, Aldevron, and Abcam; life sciences, offering instruments like mass spectrometers, flow cytometry systems, microscopes, genomics consumables, lab automation, centrifugation, particle characterization, and gene and cell therapy tools; and diagnostics, providing clinical instruments, reagents, consumables, software, and services for disease diagnosis in hospitals, physicians' offices, reference laboratories, and critical care settings through subsidiaries including Cepheid and Beckman Coulter. Danaher serves customers worldwide across biopharmaceutical, research, healthcare, and precision medicine markets, employing approximately 63,000 associates in over 125 countries. Recent developments include the 2023 acquisition of Abcam for proteomic research consumables to accelerate drug discovery; a January 2025 investment partnership with Innovaccer Inc. through Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled diagnostics and precision medicine; and a May 2025 diagnostic development and commercialization alliance with AstraZeneca to scale next-generation AI-powered diagnostics solutions.

Company News

APIChatGPT

  • seekingalpha.com

    Diamond Hill Small-Mid Cap Fund Q2 2026 Portfolio Review

  • prnewswire.com

    Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer

  • defenseworld.net

    Danaher Corporation $DHR Shares Sold by Argent Capital Management LLC

  • seekingalpha.com

    Aristotle Global Equity Advisory Q2 2026 Portfolio Review

  • defenseworld.net

    Danaher Corporation $DHR Stock Holdings Increased by ADAR1 Capital Management LLC

  • defenseworld.net

    Caxton Associates LLP Takes Position in Danaher Corporation $DHR

  • defenseworld.net

    Bank of Nova Scotia Sells 3,275 Shares of Danaher Corporation $DHR

  • fool.com

    Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity

  • zacks.com

    Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect?

  • barrons.com

    Don't Quit on Danaher Stock After Horrific Earnings Reaction

  • defenseworld.net

    Danaher Corporation $DHR Stake Raised by Andra AP fonden

  • zacks.com

    Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y

  • seekingalpha.com

    Danaher Q2 Earnings Review: Nothing Exciting For Me To Buy This Dip

  • seekingalpha.com

    Danaher Corporation (DHR) Q2 2026 Earnings Call Transcript

  • zacks.com

    Compared to Estimates, Danaher (DHR) Q2 Earnings: A Look at Key Metrics

  • marketbeat.com

    Danaher Q2 Earnings Call Highlights

  • investors.com

    Danaher Plummets After One Segment Comes In 'Surprisingly Soft'

  • investopedia.com

    5 Things to Know Before the Stock Market Opens on Tuesday

  • reuters.com

    Danaher's revenue outlook cut, biotech miss overshadow profit forecast raise

  • zacks.com

    Danaher (DHR) Q2 Earnings and Revenues Top Estimates